Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Alexander Egle Michael Steurer Thomas Melchardt Lukas Weiss Franz Josef Gassner Nadja Zaborsky Roland Geisberger Kemal Catakovic Tanja Nicole Hartmann Lisa Pleyer Daniela Voskova Josef Thaler Alois Lang Michael Girschikofsky Andreas Petzer Richard Greil

Ann Hematol

Department of Internal Medicine III with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Müllner-Hauptstr. 48, 5020, Salzburg, Austria.

Published: September 2018

The original version of this article contained a mistake. The name of Tanja Nicole Hartman should have been Tanja Nicole Hartmann. The original article has been corrected.

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828337	PMC
http://dx.doi.org/10.1007/s00277-018-3403-9	DOI Listing

Publication Analysis

Top Keywords

tanja nicole

correction fludarabine

fludarabine rituximab

rituximab escalating

escalating doses

doses lenalidomide

lenalidomide lenalidomide/rituximab

lenalidomide/rituximab maintenance

maintenance untreated

untreated chronic

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!